Drug intelligence / Profile preview

ALD-201

Development stage: Discontinued
Lead developer: Aldagen
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intracoronary

Overview

**ALD-201** is an autologous stem cell therapy derived from a unique population of bone marrow cells selected for high aldehyde dehydrogenase (ALDH) activity, developed by Aldagen (a Cytomedix subsidiary) for ischemic heart failure. It functions as an **angiogenesis inducing agent** and **cell replacement** therapy, administered via intracoronary injection to promote blood flow restoration and improve cardiac function in patients with chronic ischaemic heart disorders. Phase I trials demonstrated safety and initial evidence of enhanced perfusion and clinical status improvement, but development was discontinued.[1][3][4][5]

Other names: ALD 201ALD201ALD-201

Beyond the preview

Go deeper on ALD-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALD-201.

Explore the full profile